Caplin Point Laboratories (524742) Q4 23/24 earnings summary

Executive summary

• Achieved record consolidated revenue of ₹1,694.1 Cr in FY24, up 16% YoY, with PAT at ₹461.4 Cr, up 22% YoY.

• Maintained zero debt status, with cash reserves of ₹916 Cr and robust cash flow from operations at ₹318 Cr.

• Continued expansion in regulated markets, especially the US, and strong presence in Latin America and Africa.

• Recognized for the 7th time on Forbes Asia's "200 Best Under a Billion" list.

Financial highlights

• Operating revenue grew 16% YoY to ₹1,694.1 Cr; gross profit up 21% to ₹970 Cr.

• EBITDA increased 24% YoY to ₹618 Cr; EBIT up 25% to ₹565 Cr.

• PAT rose 22% YoY to ₹461 Cr; all profit margins improved (Gross: 57.3%, EBITDA: 35.1%, PAT: 26.2%).

• Cash reserves increased to ₹916 Cr from ₹772 Cr YoY.

• Dividend payout exceeded ₹125 Cr; final dividend of ₹2.5/share recommended.

Outlook and guidance

• Core business in Latin America and Francophone Africa expected to grow steadily with industry-average margins.

• US business identified as a primary growth engine, focusing on niche, shortage products.

• Geographic diversification underway, targeting Canada, Australia, MENA, Russia/CIS, and larger LATAM markets.

• Capex budget of ₹600–650 Cr for capacity expansion and backward integration, funded through internal accruals.